Is NMN useful for fat?

 

Globally, the proportion of adults with a body mass index >25 increased from 1975 to 2016 to approximately 39% of men and 40% of women. In 2020, the number of people suffering from obesity worldwide reached 1.211 billion, an increase of 58 million compared with 2019 and a year-on-year increase of 5.04%. Compared with people of normal weight, overweight and obese people have a 26% higher risk of developing four major chronic diseases (cardiovascular disease, malignant tumors, chronic obstructive pulmonary disease (COPD), and type 2 diabetes) in the next 10 years. % and 59%.

Researchers from Central South University in China published an article in the journal Frontiers of Endocrinology showing that ingesting NMN can combat hypoxia-induced adipose tissue fibrosis in mice. Researchers analyzed: NMN can reduce the levels of inflammatory proteins and increase the abundance of proinsulin sensitivity and the anti-inflammatory protein adiponectin. Furthermore, hypoxia increases levels of a protein that triggers inflammation and fibrosis in adipose tissue (HIF-1ɑ), but NMN attenuates its abundance. These findings suggest that NMN may avoid the snowball effect in which fibrotic adipose tissue creates more dysfunctional adipose tissue in obesity.

Proposed mechanism for the protective role of NMN in hypoxia-induced adipose tissue remodeling. Hypoxia leads to impairment of the NAMPT/NAD + /SIRT1 axis, further promoting HIF1α activation. As a result, fibrosis and inflammatory responses are significantly increased, accompanied by adipocytokine dysregulation, ultimately leading to adipose tissue remodeling. NMN restores the NAMPT/NAD + /SIRT1 axis and inhibits HIF1α activation, further attenuating adipose tissue remodeling.

These results provide further evidence for the beneficial role of NMN in regulating adipose function under hypoxic conditions.

Reference: Wu K, Li B, Ma Y, Tu T, Lin Q, Zhu J, Zhou Y, Liu N, Liu Q. Nicotinamide Mononucleotide attenuates HIF-1α activation and fibrosis in hypoxic adipose tissue via NAD+/SIRT1 axis. Front Endocrinol (Lausanne). 2023 Jan 26;14:1099134. doi: 10.3389/fendo.2023.1099134. PMID: 36777361; PMCID: PMC9909340.

*Special note - This article is for informational purposes only and cannot replace a doctor's treatment diagnosis and advice. It should not be regarded as a recommendation or proof of efficacy of the medical products involved. If it involves disease diagnosis, treatment, and rehabilitation, please be sure to go to a professional medical institution to seek professional advice.